Cefdinir: Difference between revisions
Ostermayer (talk | contribs) (Text replacement - "Category:Drugs" to "Category:Pharmacology") |
Neil.m.young (talk | contribs) (Text replacement - "4 mg" to "4mg") |
||
Line 8: | Line 8: | ||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
* | *14mg/kg/d PO divided q12-24hrs x10 days, max of 600 mg/day | ||
==Special Populations== | ==Special Populations== |
Revision as of 23:04, 18 July 2016
General
- Type: Third generation cephalosporin
- Dosage Forms: 300 mg oral solid, 125/5ml susp, 250/5ml susp
- Common Trade Names: Omnicef
Adult Dosing
- 600 mg/d divided q12-24hrs for 10 days for CAP, chronic bronchitis, acute sinusitis, strep pharyngitis, cellulitis
Pediatric Dosing
- 14mg/kg/d PO divided q12-24hrs x10 days, max of 600 mg/day
Special Populations
- Pregnancy Rating: B
- Lactation: Probably safe
- Renal Dosing
- Adult: CrCl <30, 300mg q24hrs; CrCl <10, 300mg q48hrs; supplement after HD
- Pediatric: CrCl <30, 7mg/kg q24, max 300mg/dose; supplement after HD
- Hepatic dosing not defined
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
Common
- Stool discoloration which is guiac negative and returns to normal color after cessation
Pharmacology
- Half-life:
- Metabolism:
- Excretion:
- Mechanism of Action:
Antibiotic Sensitivities[1]
Key
- S susceptible/sensitive (usually)
- I intermediate (variably susceptible/resistant)
- R resistant (or not effective clinically)
- S+ synergistic with cell wall antibiotics
- U sensitive for UTI only (non systemic infection)
- X1 no data
- X2 active in vitro, but not used clinically
- X3 active in vitro, but not clinically effective for Group A strep pharyngitis or infections due to E. faecalis
- X4 active in vitro, but not clinically effective for strep pneumonia
See Also
Source
- ↑ Sanford Guide to Antimicrobial Therapy 2014